咬肌厚度可预测头颈癌患者的癌性恶病质
本研究从20例创伤对照者和40例头颈癌患者(含恶病质与非恶病质)中计算L3骨骼肌指数(SMI)与咬肌厚度(MT),采用受试者工作特征曲线下面积(AUC-ROC)分析。结果显示,恶病质患者SMI与MT均显著降低,且两者均为恶病质的显著预测指标(AUC分别为0.985和0.805);按性别分析时,男性MT结果一致,女性呈边缘显著趋势。作者认为,与SMI相比,MT是判定头颈癌患者恶病质状态的良好替代预后生物标志物。
要点
- 恶病质头颈癌患者咬肌厚度较非恶病质者平均低2.06 mm。
- 咬肌厚度预测癌性恶病质的AUC为0.805,SMI的AUC为0.985。
- 男性中咬肌厚度预测恶病质结果与总体一致,女性呈边缘显著趋势。
核心结论
- 与SMI相比,MT是判定头颈癌患者癌性恶病质状态的良好替代预后生物标志物。
研究设计与样本
- 从20例创伤对照者(CTRL)和40例头颈癌患者(包括恶病质CA-CX与非恶病质CA-NCX)中计算SMI和MT,并对二者进行AUC-ROC分析。
主要发现
- CA-CX患者SMI较CA-NCX平均降低19.5 cm2/m2,MT较CA-NCX平均降低2.06 mm。
- SMI预测CA-CX的AUC为0.985,MT预测CA-CX的AUC为0.805,二者均为显著预测指标。
- 按性别分析时,男性MT结果与总体一致,女性MT预测CA-CX呈边缘显著趋势。
临床怎么用
- 作者认为,与SMI相比,MT可作为判定头颈癌患者癌性恶病质状态的替代预后生物标志物。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cancer cachexia is prevalent in head and neck cancer patients. The L3 skeletal muscle index (SMI) is often used to assess sarcopenia and cachexia but is infrequently able to be measured in this population. Masseter muscle thickness (MT) may serve as an alternative predictor of cachexia. METHODS: SMI and MT were calculated from 20 trauma (CTRL) and 40 cachectic (CA-CX) and non-cachectic (CA-NCX) head and neck cancer patients. Area Under the Curve of the Receiver Operating Characteristics (AUC-ROC) analysis was performed for SMI and MT. RESULTS: Both SMI and MT were significantly decreased in CA-CX patients (vs. CA-NCX mean difference -19.5 cm2/m2 and -2.06 mm, respectively) and significant predictors of CA-CX (AUC = 0.985 and 0.805, respectively). When analyzed by sex, the same findings were observed for MT in males and trended toward significance in females. CONCLUSIONS: Compared with SMI, MT is a good alternative prognostic biomarker to determine CA-CX status in HNC patients.
引用
- Balanta-Melo J, Jones AJ, Novinger LJ, et al. Masseter muscle thickness is predictive of cancer cachexia in patients with head and neck cancer. Head Neck. 2024. PMID: 38661244. doi:10.1002/hed.27789
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。